Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Development of an Inducible Co-selection System for High Efficiency Multiplex Editing
EF 2023-24
Résumé
Next-generation CRISPR technologies, like base editing, enable precise multiplex engineering of immune cells creating promising new treatment options for cancer patients, as recently observed in refractory cancer patients who entered remission. However, the potential for therapeutic applications of base editing is hindered by low editing efficiency. I propose to develop an inducible suicide co-selection system to improve multiplex editing efficiency of human primary T-cells. The inducible caspase 9 (iC9) suicide gene is a safety switch commonly used to eliminate engineered cells in therapies to circumvent potential fatal adverse effects. I hypothesize that iC9 can serve as a safe, rapid, and robust co-selection system for enriching multiplex edited human primary T-cells. This approach includes co-editing T-cell-specific therapeutic genes while inactivating iC9 to protect the edited population from apoptosis upon treatment with the chemical inducer of dimerization (CID). CID induces apoptosis in cells with intact iC9 resulting in the survival of only multiplex edited cells. I will assess the enhancement of anti-tumor function of engineered T-cells in a co-culture assay with cancer cells. This approach for high efficiency multiplex genome editing of human primary T-cells leverages the FDA-approved iC9 system and non-toxic CID. The convergence of powerful cell-based therapies and rapidly emerging genome editing technologies holds great potential for enhancing the utility of cancer immunotherapy. This work will establish an innovative approach to enable high efficiency engineering of therapeutic immune cells with improved capabilities by limiting T-cell dysfunction and exhaustion and enhancing targeting against tumors for the development of next-generation immunotherapies.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
505958
Name
Curry Jada
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of an Inducible Co-selection System for High Efficiency Multiplex Editing
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Base Editing; Cancer Therapies; Car-T Cell Therapies; Cell Suicide; Co-Selection System; Crispr/Cas9 Technologies; Genome Editing; Immunotherapies; Inducible Caspase 9; Prime Editing
Abstract
Next-generation CRISPR technologies, like base editing, enable precise multiplex engineering of immune cells creating promising new treatment options for cancer patients, as recently observed in refractory cancer patients who entered remission. However, the potential for therapeutic applications of base editing is hindered by low editing efficiency. I propose to develop an inducible suicide co-selection system to improve multiplex editing efficiency of human primary T-cells. The inducible caspase 9 (iC9) suicide gene is a safety switch commonly used to eliminate engineered cells in therapies to circumvent potential fatal adverse effects. I hypothesize that iC9 can serve as a safe, rapid, and robust co-selection system for enriching multiplex edited human primary T-cells. This approach includes co-editing T-cell-specific therapeutic genes while inactivating iC9 to protect the edited population from apoptosis upon treatment with the chemical inducer of dimerization (CID). CID induces apoptosis in cells with intact iC9 resulting in the survival of only multiplex edited cells. I will assess the enhancement of anti-tumor function of engineered T-cells in a co-culture assay with cancer cells. This approach for high efficiency multiplex genome editing of human primary T-cells leverages the FDA-approved iC9 system and non-toxic CID. The convergence of powerful cell-based therapies and rapidly emerging genome editing technologies holds great potential for enhancing the utility of cancer immunotherapy. This work will establish an innovative approach to enable high efficiency engineering of therapeutic immune cells with improved capabilities by limiting T-cell dysfunction and exhaustion and enhancing targeting against tumors for the development of next-generation immunotherapies.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Curry, Jada
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~